Embecta Corp./$EMBC
1D1W1MYTD1Y5YMAX
Capital at risk
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
- Ticker
- $EMBC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,850
- Headquarters
- Parsippany, United States
- Website
- www.embecta.com
Embecta Corp. Metrics
BasicAdvanced
$280M
3.36
$1.47
0.79
$0.46
0.81%
Price and volume
Market cap
$280M
Beta
0.79
52-week high
$15.55
52-week low
$2.77
Average daily volume
1.7M
Dividend rate
$0.46
Financial strength
Current ratio
1.68
Quick ratio
0.945
Long term debt to equity
-219.21
Total debt to equity
-242.533
Dividend payout ratio (TTM)
31.09%
Interest coverage (TTM)
2.36%
Profitability
EBITDA (TTM)
281.5
Gross margin (TTM)
58.42%
Net profit margin (TTM)
8.59%
Operating margin (TTM)
22.96%
Effective tax rate (TTM)
30.00%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
12.24%
Return on equity (TTM)
-13.65%
Valuation
Price to earnings (TTM)
3.362
Price to revenue (TTM)
0.285
Price to book
-0.46
Price to tangible book (TTM)
-0.4
Price to free cash flow (TTM)
1.764
Free cash flow yield (TTM)
56.69%
Free cash flow per share (TTM)
2.801
Dividend yield (TTM)
9.31%
Forward dividend yield
0.81%
Growth
Revenue change (TTM)
-7.60%
Earnings per share change (TTM)
3.42%
3-year revenue growth (CAGR)
-2.92%
3-year earnings per share growth (CAGR)
21.14%
3-year dividend per share growth (CAGR)
-8.48%
What the Analysts think about Embecta Corp.
Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.
Analyst projections of the future price of Embecta Corp. stock.
Embecta Corp. Financial Performance
Revenues and expenses
Embecta Corp. Earnings Performance
Company profitability
Upcoming events
Embecta Corp. News
AllArticlesVideos
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp3 weeks ago
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp4 weeks ago
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Business Wire4 weeks ago
Funds containing Embecta Corp.
AllEURGBPUSD
Fund name | Fund size | $EMBC weighting |
|---|---|---|
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.